美股详情

本页面由Tiger Trade Technology Pte. Ltd.提供服务

Kardigan

22.00

+6.0037.50%

盘后：22.000.00000.00%19:59 EDT

成交量：584.44万

成交额：1.14亿

市值：19.29亿

市盈率：-8.39

高：23.75

开：16.25

低：16.25

收：16.00

52周最高：23.75

52周最低：16.25

股本：8,767.25万

流通股本：2,333.33万

量比：- -

换手率：25.05%

股息：- -

股息率：- -

每股收益(TTM):-2.6230

净资产收益率：--

总资产收益率：--

市净率：-6.42

市盈率(LYR):- -

数据加载中...

总览公司新闻公告

公司资料

公司名字：

Kardigan

交易所：

NASDAQ

成立时间：

2023

员工人数：

241

公司地址：

506 Carnegie Center Drive,Suite 201,Princeton,New Jersey,United States

官网：

http://www.kardigan.bio

邮编：

08540

电话：

传真：

- -

简介：

Kardigan, Inc.于2023年8月根据特拉华州法律注册成立。该公司是一家临床阶段的精准治疗公司，致力于开发针对特定心血管疾病根本病因的药物，这些疾病目前尚无获批疗法。公司的使命是并行开发多种靶向心血管疗法，使心血管疾病患者早日获得应有的治愈。公司目前有三个处于后期临床开发阶段的项目：Danicamtiv、Ataciguat和Tonlamarsen，这些项目针对的适应症目前尚无获批疗法。管理团队拥有深厚的心血管疾病领域知识，并运用创新的药物开发方法，结合公司专有的 Prolaio 平台的数据和分析技术，以高效执行的方式快速交付成果。公司在心血管药物开发中秉持高度精准的理念，着眼于疾病的根本原因，而非后期出现的心血管症状。

董事

名称

职位

Tassos Gianakakos

Chair and Chief Executive Officer and Director

David Meeker

Director

Douglas Giordano

Director

Kim Popovits

Director

Paul Berns

Director

Tim Walbert

Director

股东

名称

职位

Tassos Gianakakos

Chair and Chief Executive Officer and Director

Brianne Puglisi

Chief Financial Officer

Andy Pasternak

Chief Strategy Officer

Jay Edelberg

Chief Medical Officer

John B. Moriarty, Jr.

Chief Legal Officer and Corporate Secretary

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/stock/KARD/company"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"KARD","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"KARD\",,,,,undefined,":{"symbol":"KARD","market":"US","secType":"STK","nameCN":"Kardigan","latestPrice":22,"timestamp":1781812800000,"preClose":16,"halted":0,"volume":5844442,"hourTrading":{"tag":"盘后","latestPrice":22,"preClose":22,"latestTime":"19:59 EDT","volume":49387,"amount":1039648.3023,"timestamp":1781827198381,"change":0,"changeRate":0,"amplitude":0.086818},"delay":0,"changeRate":0.375,"floatShares":23333300,"shares":87672455,"eps":-2.623,"marketStatus":"休市中","change":6,"latestTime":"06-18 16:00:00 EDT","open":16.25,"high":23.75,"low":16.25,"amount":113636875.58236,"amplitude":0.46875,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-2.623,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1782115200000},"marketStatusCode":7,"adr":0,"listingDate":1781755200000,"exchange":"NASDAQ","adjPreClose":16,"postHourTrading":{"tag":"盘后","latestPrice":22,"preClose":22,"latestTime":"19:59 EDT","volume":49387,"amount":1039648.3023,"timestamp":1781827198381,"change":0,"changeRate":0,"amplitude":0.086818},"volumeRatio":0},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"KARD\",,,,,undefined,":{"symbol":"KARD","floatShares":23333300,"roa":"--","roe":"--","lyrEps":0,"shares":87672455,"dividePrice":0,"high":23.75,"amplitude":0.46875,"preClose":16,"low":16.25,"week52Low":16.25,"pbRate":"-6.42","week52High":23.75,"institutionHeld":0,"latestPrice":22,"eps":-2.623,"divideRate":0,"volume":5844442,"delay":0,"ttmEps":-2.623,"open":16.25,"prevYearClose":16,"prevWeekClose":16,"prevMonthClose":16,"prevQuarterClose":16,"fiveDayClose":16,"twentyDayClose":16,"sixtyDayClose":16},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/KARD\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"KARD\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"KARD\",market:\"US\",delay:false,,,undefined,":{},"@#url:\"stock.company.info\",,undefined,":{"stockCompanyProfile":{"companyId":1916374431,"yearFounded":2023,"employeeNum":241,"address":"506 Carnegie Center Drive,Suite 201,Princeton,New Jersey,United States","zipCode":"08540","officePhone":"(415) 573-3220","fiscalYearEnd":"12-31"},"stockCompanyDetail":{"websiteUrl":"http://www.kardigan.bio","stockEarnings":[{"period":"1week","weight":0.375},{"period":"ytd","weight":0.375}],"compareEarnings":[{"period":"1week","weight":0.0122},{"period":"1month","weight":0.0177},{"period":"3month","weight":0.1514},{"period":"6month","weight":0.0972},{"period":"1year","weight":0.2499},{"period":"ytd","weight":0.0951}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Kardigan, Inc.于2023年8月根据特拉华州法律注册成立。该公司是一家临床阶段的精准治疗公司，致力于开发针对特定心血管疾病根本病因的药物，这些疾病目前尚无获批疗法。公司的使命是并行开发多种靶向心血管疗法，使心血管疾病患者早日获得应有的治愈。公司目前有三个处于后期临床开发阶段的项目：Danicamtiv、Ataciguat和Tonlamarsen，这些项目针对的适应症目前尚无获批疗法。管理团队拥有深厚的心血管疾病领域知识，并运用创新的药物开发方法，结合公司专有的 Prolaio 平台的数据和分析技术，以高效执行的方式快速交付成果。公司在心血管药物开发中秉持高度精准的理念，着眼于疾病的根本原因，而非后期出现的心血管症状。","exchange":"NASDAQ","name":"Kardigan","nameEN":"Kardigan"}},"@#url:\"https://hq.skytigris.cn/fundamental/company/manager/list\",params:#symbol:\"KARD\",market:\"US\",,,undefined,":{"directors":[{"name":"Tassos Gianakakos","position":"Chair and Chief Executive Officer and Director"},{"name":"David Meeker","position":"Director"},{"name":"Douglas Giordano","position":"Director"},{"name":"Kim Popovits","position":"Director"},{"name":"Paul Berns","position":"Director"},{"name":"Tim Walbert","position":"Director"}],"executives":[{"name":"Tassos Gianakakos","position":"Chair and Chief Executive Officer and Director"},{"name":"Brianne Puglisi","position":"Chief Financial Officer"},{"name":"Andy Pasternak","position":"Chief Strategy Officer"},{"name":"Jay Edelberg","position":"Chief Medical Officer"},{"name":"John B. Moriarty, Jr.","position":"Chief Legal Officer and Corporate Secretary"}]}}}